Overview

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
Phase:
Phase 2
Details
Lead Sponsor:
ISA Pharmaceuticals
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Cemiplimab